We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBetterLife Pharma Inc

BetterLife Pharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.14 USD -0.00 ( 2.10%)
Last update at 2026-11-11T21:00:00Z
VOLUME
130503
Market Cap
8.09M

Momentum Score

…

BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety disorder, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat anxiety related disorders, including benzodiazepine dependency. It is also developing MM-001, a topical cream formulation of interferon-alpha 2b, which has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation that has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.14
Low
0.14
High
52 Week Price Range
0.03
Low
0.09
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BetterLife Pharma Inc is an OTCQB-listed small-cap company that identifies as operating in the pharmaceutical/biotech sector, although public disclosures and filings are limited. Long-term growth may come from product development, regulatory approvals and commercial partnerships. Investors may find potential upside from development milestones, but limited disclosure raises uncertainty.

Primary risks include limited public disclosure, small market capitalization with low liquidity, reliance on external financing, and regulatory or clinical development setbacks.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.14
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-0.02M
Debt / Equity
-
ROE
-4416.54%
Net Debt
0.91M
ROCE
64.61%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Income before tax -3.62M -2.90M -9.37M -11.99M -36.35M
Minority interest 0.10M 0.01M 0.36M - -
Net income -3.52M -2.89M -9.02M -12.16M -36.35M
Selling general administrative 4.30M 2.64M 6.56M 4.53M 7.56M
Reconciled depreciation 0.00M 0.00M 0.02M 0.02M 0.34M
Ebit - - - -9.97M -7.95M
Ebitda - - -9.29M -11.92M -35.97M
Operating income -4.72M -3.21M -9.26M -9.97M -7.95M
Interest expense 0.32M 0.05M 0.07M 0.06M 0.04M
Tax provision - 0.00M 0.00M 0.17M -
Interest income - - 0.00M 0.00M 0.00M
Net interest income 0.44M -0.08M -0.09M -1.28M -0.22M
Income tax expense - - - 0.17M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 4.72M 3.21M 9.26M 9.97M 7.95M
Total other income expense net 0.66M 0.40M -0.02M -0.74M -28.17M
Net income from continuing ops -3.62M -2.90M -9.37M -12.16M -36.35M
Net income applicable to common shares - - - -12.16M -36.35M
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Total assets 0.22M 0.32M 0.07M 1.16M 1.34M
Other current assets 0.21M 0.25M - - -
Total liab 7.59M 8.02M 7.61M 5.04M 5.95M
Total stockholder equity -10.68M -10.81M -10.73M -3.88M -4.61M
Other current liab 0.31M 0.00M - 0.38M 0.18M
Common stock - - - 75.38M 63.67M
Capital stock 79.97M 78.46M 76.57M 75.38M 63.67M
Retained earnings -118.60M -115.08M -112.19M -103.17M -91.01M
Other liab - - - 0.86M 0.13M
Cash 0.01M 0.04M 0.01M 0.17M 0.15M
Total current liabilities 7.54M 6.83M 7.15M 4.14M 5.85M
Net debt 0.91M 0.29M 0.07M 0.14M 0.35M
Short long term debt 0.87M - 0.08M 0.28M 0.50M
Other stockholder equity - - - 23.91M 22.73M
Property plant equipment - - - 0.02M 0.04M
Total current assets 0.22M 0.32M 0.07M 1.14M 1.33M
Net tangible assets - - - -3.88M -4.61M
Net receivables 0.01M 0.04M 0.02M 0.32M 0.52M
Long term debt 0.05M 0.33M - 0.03M -
Accounts payable 4.50M 4.98M 5.44M 3.34M 4.50M
Non current assets total 0.00M 0.00M 0.00M 0.02M 0.04M
Capital lease obligations 0.38M 1.14M 1.11M 1.08M -
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Investments - - 0.00M 0.00M -0.07M
Change to liabilities - - 0.00M -1.16M -0.99M
Total cashflows from investing activities - - - - -0.07M
Net borrowings 1.22M 0.30M - -0.13M 0.10M
Total cash from financing activities 1.99M 2.50M 1.34M 11.23M 4.09M
Change to operating activities - - - -0.51M -0.20M
Net income -3.52M -2.89M -9.02M -12.16M -36.35M
Change in cash -0.03M 0.03M -0.17M 0.02M -3.13M
Begin period cash flow 0.04M 0.01M 0.17M 0.15M 3.28M
End period cash flow 0.01M 0.04M 0.01M 0.17M 0.15M
Total cash from operating activities -2.02M -2.47M -1.50M -11.20M -7.16M
Issuance of capital stock 0.70M 2.20M 0.83M 11.44M 1.29M
Depreciation 0.00M 0.00M 0.02M 0.02M 0.34M
Change to account receivables - - - 0.18M -0.35M
Other cashflows from financing activities - - 0.19M 1.08M 2.61M
Change to netincome - - - 2.25M 30.39M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.01M
Change in working capital 0.75M 0.32M 3.43M -1.32M -1.54M
Stock based compensation 2.05M 0.50M 0.95M 1.23M 0.83M
Other non cash items -1.40M -0.09M 3.07M 0.97M 18.21M
Free cash flow -2.02M -2.47M -1.50M -11.20M -7.26M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
BETRF
BetterLife Pharma Inc		 -0.00
2.10%		 0.14 - - - 13.65 -0.81
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

BetterLife Pharma Inc

BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety disorder, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat anxiety related disorders, including benzodiazepine dependency. It is also developing MM-001, a topical cream formulation of interferon-alpha 2b, which has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation that has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

1275 West 6th Avenue, Vancouver, BC, Canada, V6H 1A6

604 221 0595

https://www.abetterlifepharma.com

Name Title Year Born
Dr. Ahmad Doroudian Ph.D. Founder, CEO & Chairman 1960
Ms. Moira Ong C.A., CPA, CA, CFA Chief Financial Officer 1975
Dr. Hooshmand Sheshbaradaran Ph.D. Chief Operating Officer 1968
Mr. Scott Rudge Ph.D. Head of CMC NA
Anthony Calandra Ph.D. Head of Regulatory NA
Dr. Abdi Ghaffari Ph.D. Head of Preclinical & Toxicology NA
Dr. Hooshmand Sheshbaradaran Ph.D. Chief Operating Officer 1957
Dr. Stephen Sangha Corporate Development Advisor NA
Ms. Moira Ong C.A., CPA, CFA Chief Financial Officer 1975
Dr. Stephen Sangha Corporate Development Advisor & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…